Treprostinil (Tyvaso) vs Treprostinil (Yutrepia, Liquidia)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Treprostinil (Tyvaso)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT00147199 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).

Next expected readout: December 2027 · NCT07177703 (registry estimate)

Reported efficacy

Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)

Result source: NCT00147199

Treprostinil (Yutrepia, Liquidia)

Marketed by Liquidia Corporation

Approved in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin analogue, inhaled dry powder)
Weak signal

NCT03399604 · Phase 3 · completed

The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.

Next expected readout: May 2027 · NCT07759804 (registry estimate)

Reported efficacy

Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)

Result source: NCT03399604

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Treprostinil (Tyvaso): 4 of 4 rows · Treprostinil (Yutrepia, Liquidia): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTreprostinil (Tyvaso)Treprostinil (Yutrepia, Liquidia)
Dropout rate
11.3%a
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
0%
NCT01268553 · Phase 4 · registry result, not featured evidence
11%
NCT00741819 · Phase 4 · registry result, not featured evidence
0%
NCT00705133 · Phase 2 · registry result, not featured evidence
—LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
24%LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Discontinued due to AEs
—a
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
—
NCT01268553 · Phase 4 · registry result, not featured evidence
4.1%
NCT00741819 · Phase 4 · registry result, not featured evidence
—
NCT00705133 · Phase 2 · registry result, not featured evidence
—LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
—LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Serious AEs
7.8%a
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
0%
NCT01268553 · Phase 4 · registry result, not featured evidence
13.7%
NCT00741819 · Phase 4 · registry result, not featured evidence
0%
NCT00705133 · Phase 2 · registry result, not featured evidence
12.4%LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
—LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Most frequent reported AEs
a
cough 53.9% (placebo 29.2%)
headache 40.9% (placebo 22.5%)
nausea 19.1% (placebo 10.8%)
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 2 more results
cough 74%
headache 43.8%
nausea 30.1%
NCT00741819 · Phase 4 · registry result, not featured evidence
general prostacyclin adverse reaction profile 100%
NCT00705133 · Phase 2 · registry result, not featured evidence
cough 33.9%
headache 19%
upper respiratory tract infection 14.9%
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Treprostinil (Tyvaso)

Six Minute Walk Distance Peak Change 21.6 vs 3 placebo m @ 12wk
absolute change · m
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
21.6 vs 3 placebo m @ 6wk
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Clinical Worsening 4 vs 6 placebo count @ 12wk
event rate · count
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Borg Dyspnea 0 vs 0 placebo score @ 12wk
absolute change · score
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Six Minute Walk Distance Trough Change 12.4 vs 0.8 placebo m @ 12wk
absolute change · m
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Mlwhf Total -3 vs 0 placebo score @ 12wk
absolute change · score
Global Score
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Signs and Symptoms 0 vs 0 placebo score @ 12wk
absolute change · score
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Clinical Worsening Free 100% (n=6) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
6MWD - Change 20 m @ 12wk
absolute change · m
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
show 1 more result
230 m @ 12wk
NCT00705133 · Phase 2 · registry result, not featured evidence
Ventilatory Efficiency Change Slope 1.2 ratio @ 12wk
ratio to baseline · ratio
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
CAMPHOR -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
6MWD - Change 16 m @ 12wk
absolute change · m
No placebo or comparator arm
Change from Baseline
NCT00741819 · Phase 4 · registry result, not featured evidence
QOL -2.4 score @ 12wk
absolute change · score
No placebo or comparator arm
Change in Quality of Life Score
NCT00741819 · Phase 4 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

Pulmonary Hypertension Associated with Interstitial Lung Disease

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline

Treprostinil (Tyvaso)

Marketed by United Therapeutics

Approved in Pulmonary Hypertension Associated with Interstitial Lung Diseasesmall molecule
Reliable signal

NCT02630316 · Phase 2/3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 326 people, and inhaled treprostinil significantly improved six-minute walk distance at week 16 compared with placebo (p=0.0043). The trial reported a sample-size calculation for this endpoint and enrolled more participants than the calculation required.

Reported efficacy

Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 (Baseline and Week 16): Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results). (met)

Result source: NCT02630316

Treprostinil (Yutrepia, Liquidia)

Marketed by Liquidia Corporation

Approved in Pulmonary Hypertension Associated with Interstitial Lung Diseasesmall molecule (prostacyclin analogue, inhaled dry powder)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Pulmonary Hypertension Associated with Interstitial Lung Disease

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Treprostinil (Yutrepia, Liquidia): no structured comparison results are available for Pulmonary Hypertension Associated with Interstitial Lung Disease.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Treprostinil (Tyvaso)

Six Minute Walk Distance Peak Change 6 vs -9 placebo m @ 16wk
absolute change · m
NCT02630316 · Phase 2/3
show 1 more result
8 vs -3 placebo m @ 12wk
NCT02630316 · Phase 2/3
NT-proBNP Change -22.65 vs 20.65 placebo pg/mL @ 16wk
absolute change · pg/mL
NCT02630316 · Phase 2/3
Clinical Worsening 22.7% (n=163) vs 33.1% (n=163) placebo @ 16wk
event count · % of participants
NCT02630316 · Phase 2/3 · converted to % from 37 Participants as posted
Six Minute Walk Distance Trough Change 0 vs -9 placebo m @ 15wk
absolute change · m
NCT02630316 · Phase 2/3
Available safety results

Treprostinil (Tyvaso)

Dropout rate
—Active Inhaled Treprostinil
NCT02630316 · Phase 2/3
show 1 more result
20.2%Inhaled Treprostinil
NCT02630316 · Phase 2/3
Discontinued due to AEs
—Active Inhaled Treprostinil
NCT02630316 · Phase 2/3
show 1 more result
—Inhaled Treprostinil
NCT02630316 · Phase 2/3
Serious AEs
23.3%Active Inhaled Treprostinil
NCT02630316 · Phase 2/3
show 1 more result
—Inhaled Treprostinil
NCT02630316 · Phase 2/3
Most frequent reported AEs
cough 43.6% (placebo 33.1%)
headache 27.6% (placebo 19.6%)
dyspnoea 25.2% (placebo 31.3%)
NCT02630316 · Phase 2/3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Tyvaso)'s landscape · Treprostinil (Yutrepia, Liquidia)'s landscape